VEGFA and kidney cancer: In keeping with the pre-clinical models, drugs that inhibit the kinase activity of the receptors for Vascular Endothelial Growth Factor (VEGF), a critical HIF target gene, have been proved to be clinically effective and have become major therapeutic agents for treating kidney cancer [18].